Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Monte Rosa Therapeutics Inc
Operating Income
Monte Rosa Therapeutics Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
M
|
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
|
Operating Income
-$143.3m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is Monte Rosa Therapeutics Inc's Operating Income?
Operating Income
-143.3m
USD
Based on the financial report for Dec 31, 2023, Monte Rosa Therapeutics Inc's Operating Income amounts to -143.3m USD.
What is Monte Rosa Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 3Y
-72%
Over the last year, the Operating Income growth was -28%. The average annual Operating Income growth rates for Monte Rosa Therapeutics Inc have been -72% over the past three years .